Public consultation on interim decisions to amend the Poisons Standard - ACMS, ACCS & Joint ACMS-ACCS, NOVEMBER 2022

Closed 3 Mar 2023

Opened 3 Feb 2023

Contact

Medicines Scheduling

1800 020 653

medicines.scheduling@health.gov.au

Feedback updated 3 May 2023

We asked

Between 3 February 2023 to 3 March 2023, we sought submissions from the public on the Delegate’s interim decisions on substances previously discussed at the November 2022 meetings of the Advisory Committees on Medicines and Chemicals Scheduling. Respondents were given the choice to indicate their support or opposition to the proposed amendments using survey buttons, with or without a written response.

You said

A total of 12 responses were received through the consultation. A breakdown of the submissions can be found below.

Ivermectin: 7 responses were received, 2 supportive of interim decision and 4 opposed. Of these, 1 in full support of the interim decision, and 3 submissions in opposition contained a written component. 1 submission contained a written component without indicating support or opposition.

Brimonidine: 2 responses were received, 1 in support of the interim decision and 1 in opposition. Only the submission in support of the interim decision contained a written component.

Fexofenadine: 2 responses were received, with one response in support of the interim decision and one against. Only the submission in support of the interim decision contained a written component.

Ibuprofen: 6 responses were received, 3 in support and 3 in opposition of the interim decision. Of these, 2 submissions in support of the interim decision and 2 in opposition of the interim decision contained written components.

Melatonin: 5 responses were received, 2 in full support, 2 in partial support and 1 in opposition of the interim decision. Of these, 2 submissions in partial support and 1 submission in full support contained a written component.

Green tea extract: 5 responses were received, 3 in full support and 2 in opposition to the interim decision. Of these, 3 submissions in support contained a written component and 1 submission in opposition contained a written component.

Ethalfluralin: 2 responses were received, 1 in support and 1 in opposition of the interim decision. No written components were received.

Tigolaner: 1 vote was received in opposition of the proposed amendment without a written component.

We did

The Delegates considered all submissions prior to making their final decision. The final decisions on the proposed amendments to the Poisons Standard were published on 3 MAY 2023.

Published responses

View submitted responses where consent has been given to publish the response.

Overview

Interim decisions regarding substances discussed at the expert advisory meetings. 

Please note that this consultation is for substances other than paracetamol. If you wish to comment the proposed interim decision in relation to paracetamol please see the link below:

This consultation is for interim decisions made in relation to the other substances that were discussed at the November 2022 meetings of the Advisory Committee on Medicines Scheduling (ACMS) and the Advisory Committee on Chemicals Scheduling (ACCS).

Kindly note that the interim decisions published below may differ from the initial proposal. Please read through the proposed interim decisions which can be accessed through the links below and are available on the consultation page for your convenience.

Once you are familiar with the interim decision, please provide your comments and votes in relation to the interim decision.

The closing date for this consultation is close of business 3 MARCH 2023. All submissions received by the deadline will be considered by the delegate before they make an interim decision.

The interim decisions under consultation are detailed in the Public notice of interim decisions November 2023 which can be accessed below: 

Substances for which public comment is sought:

  • Ivermectin
  • Brimonidine
  • Fexofenadine
  • Ibuprofen
  • Melatonin 
  • Green tea extract
  • Ethalfluralin
  • Tigolaner

What happens next

All public submissions will be published on the TGA website at Public submissions on scheduling matters, unless marked confidential or indicated otherwise in the submission information (see Privacy and your Personal information).

Public submissions are an important part of the process for amending the Poison Standard, and are published on the TGA website using the consultation hub.  Submissions by the public may not reflect the views of the Department of Health and Aged Care or TGA.  Published submissions should not be taken as being endorsed by the Department or TGA.

Following consideration of public submissions received before the closing date and advice from the expert advisory committees, decisions on the proposed amendments are anticipated to be published as final decisions on the TGA website: Scheduling delegate's final decisions at a later date.

Audiences

  • Aboriginal and Torres Strait Islander People
  • Seniors
  • Men
  • Women
  • Carers and guardians
  • Families
  • Parents
  • Young people
  • Academics
  • Non-government organisations
  • State government agencies
  • Commonwealth agencies
  • Health professionals
  • Health workforce
  • General public
  • Community groups
  • Businesses
  • Contracted Service Providers
  • Aged care service providers
  • Aged care workforce
  • Aged care professionals
  • BPRU staff
  • Graduates
  • Online and Publications staff
  • Secretariat
  • PCCD
  • Health staff
  • HPRG (TGA) Staff
  • Prescription medicines
  • Complementary medicines
  • Over-the-counter medicines
  • Medical Devices & IVDs
  • Biologicals
  • Other

Interests

  • Policy Development